The kidneys play a pivotal role in the regulation of electrolyte and acid-base balance. With progressive loss of kidney function, derangements in electrolytes and acid-base inevitably occur and contribute to poor patient outcomes. As chronic kidney disease (CKD) has become a worldwide epidemic, medical providers are increasingly confronted with such problems. Adequate diagnosis and treatment will minimize complications and can potentially be lifesaving. In this review, we discuss the current understanding of the disease process, clinical presentation, diagnosis and treatment strategies, integrating up-to-date knowledge in the field. Although electrolyte and acid-base derangements are significant causes of morbidity and mortality in CKD and end-stage renal disease patients, they can be effectively managed through a timely institution of combined preventive measures and pharmacological therapy. Exciting advances and several upcoming outcome trials will provide further information to guide treatment and improve patient outcomes.

Keywords:
Dyskalemia, Acidosis, Mineral bone disorder, Dysnatremia , Dysmagnesemia, Chronic kidney disease, End-stage renal disease
1.
United States Renal Data System: 2015 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, National Institutes of Health, 2015. www.usrds.org/2015/view/Default.aspx (cited October 8, 2016).
2.
De Nicola L, Zoccali C: Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant 2016;31:331-335.
3.
Luo J, et al: Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol 2016;11:90-100.
4.
Sarafidis PA, et al: Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012;7:1234-1241.
5.
Einhorn LM, et al: The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156-1162.
6.
Chang AR, et al: Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 2016;67:1181-1188.
7.
Ingelfinger JR: A new era for the treatment of hyperkalemia? N Engl J Med 2015;372:275-277.
8.
Meng QH, Wagar EA: Pseudohyperkalemia: a new twist on an old phenomenon. Crit Rev Clin Lab Sci 2015;52:45-55.
9.
Parham WA, et al: Hyperkalemia revisited. Tex Heart Inst J 2006;33:40-47.
10.
Khattak HK, et al: Recurrent life-threatening hyperkalemia without typical electrocardiographic changes. J Electrocardiol 2014;47:95-97.
11.
Barold SS, Herweg B: The effect of hyperkalaemia on cardiac rhythm devices. Europace 2014;16:467-476.
12.
Epstein M, et al: Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(11 suppl):S212-S220.
13.
Evans BM, et al: Ion-exchange resins in the treatment of anuria. Lancet 1953;265:791-795.
14.
Lepage L, et al: Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol 2015;10:2136-2142.
15.
Harel Z, et al: Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 2013;126:264.e9-e24.
16.
Li L, et al: Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther 2016;21:456-465.
17.
Weir MR, et al: Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372:211-221.
18.
Bakris GL, et al: Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-161.
19.
Weir MR, et al: Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int 2016;90:696-704.
20.
Gekle M, Grossmann C: Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 2009;458:231-246.
21.
Ritz E, Tomaschitz A: Aldosterone, a vasculotoxic agent - novel functions for an old hormone. Nephrol Dial Transplant 2009;24:2302-2305.
22.
Bushinsky DA, et al: Effect of patiromer on urinary ion excretion in healthy adults. Clin J Am Soc Nephrol 2016;pii:CJN.01170216.
23.
Packham DK, et al: Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372:222-231.
24.
Kosiborod M, et al: Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014;312:2223-2233.
25.
Bushinsky DA: National Kidney Foundation 2016 Spring Clinical Meetings Abstracts April 27-May 1, 2016. Patiromer Decreases Serum Potassium in Patients on HD. Am J Kidney Dis 2016;67:A1-A118.
26.
Adrogué HJ, Madias NE: Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 2007;356:1966-1978.
27.
Tobian L, et al: Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered. Hypertension 1985;7(3 pt 2):I110-I114.
28.
Chiu DY, et al: Sudden cardiac death in haemodialysis patients: preventative options. Nephrology (Carlton) 2014;19:740-749.
29.
Collins AJ, et al: US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 2014;63(1 suppl):A7.
30.
Ohtake T, et al: High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005;16:1141-1148.
31.
Buiten MS, et al: The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 2014;100:685-690.
32.
Pun PH, et al: Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011;79:218-227.
33.
Jadoul M, et al: Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2012;7:765-774.
34.
Foley RN, et al: Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011;365:1099-1107.
35.
Bleyer AJ, et al: Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69:2268-2273.
36.
Bleyer AJ, Russell GB, Satko SG: Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999;55:1553-1559.
37.
Santoro A, et al: Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal. Nephrol Dial Transplant 2008;23:1415-1421.
38.
Vallet M, et al: Urinary ammonia and long-term outcomes in chronic kidney disease. Kidney Int 2015;88:137-145.
39.
Wrong O, Davies HE: The excretion of acid in renal disease. Q J Med 1959;28:259-313.
40.
Kim HY, et al: Effect of reduced renal mass on renal ammonia transporter family, Rh C glycoprotein and Rh B glycoprotein, expression. Am J Physiol Renal Physiol 2007;293:F1238-F1247.
41.
Karim Z, Attmane-Elakeb A, Bichara M: Renal handling of NH4+ in relation to the control of acid-base balance by the kidney. J Nephrol 2002;15(suppl 5):S128-S134.
42.
Nath KA, Hostetter MK, Hostetter TH: Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985;76:667-675.
43.
Wesson DE, Simoni J: Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int 2010;78:1128-1135.
44.
Wesson DE, et al: Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 2011;300:F830-F837.
45.
Shah SN, et al: Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis 2009;54:270-277.
46.
Raphael KL, et al: Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int 2011;79:356-362.
47.
Kanda E, et al: High serum bicarbonate level within the normal range prevents the progression of chronic kidney disease in elderly chronic kidney disease patients. BMC Nephrol 2013;14:4.
48.
Raphael KL, et al: Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease. Nephrology (Carlton) 2014;19:648-654.
49.
Kopple JD, Kalantar-Zadeh K, Mehrotra R: Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl 2005;95:S21-S27.
50.
Kraut JA, Kurtz I: Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005;45:978-993.
51.
Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 2009;24:1232-1237.
52.
Driver TH, et al: Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2014;64:534-541.
53.
de Brito-Ashurst I, et al: Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009;20:2075-2084.
54.
Mahajan A, et al: Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010;78:303-309.
55.
Phisitkul S, et al: Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010;77:617-623.
56.
Abramowitz MK, et al: Effects of oral sodium bicarbonate in patients with CKD. Clin J Am Soc Nephrol 2013;8:714-720.
57.
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;(suppl):73.
58.
Goraya N, et al: Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int 2014;86:1031-1038.
59.
Dobre M, et al: Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): a report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc 2015;4:pii:e001599.
60.
Witham MD, et al: Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial. Trials 2015;16:326.
61.
Gaggl M, et al: Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study). Trials 2013;14:196.
62.
Di Iorio B, et al: A prospective, multicenter, randomized, controlled study: the correction of metabolic acidosis with use of bicarbonate in Chronic Renal Insufficiency (UBI) Study. J Nephrol 2012;25:437-440.
63.
Tentori F, et al: Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2013;62:738-746.
64.
Moe S, et al: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
65.
Levin A, et al: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38.
66.
Tejwani V, Qian Q: Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. Nutrients 2013;5:1913-1936.
67.
Moranne O, et al: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009;20:164-171.
68.
Reynolds JL, et al: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-2867.
69.
Mathew S, et al: The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008;19:1092-1105.
70.
Chen NX, Moe SM: Pathophysiology of vascular calcification. Curr Osteoporos Rep 2015;13:372-380.
71.
Goodman WG, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
72.
O'Seaghdha CM, et al: Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2011;26:2885-2890.
73.
Kestenbaum B, et al: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
74.
Chartsrisak K, et al: Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. BMC Nephrol 2013;14:14.
75.
Jung SY, et al: Electrolyte and mineral disturbances in septic acute kidney injury patients undergoing continuous renal replacement therapy. Medicine (Baltimore) 2016;95:e4542.
76.
Da J, et al: Serum phosphorus and progression of CKD and mortality: a meta-analysis of cohort studies. Am J Kidney Dis 2015;66:258-265.
77.
Dhingra R, et al: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-885.
78.
Tonelli M, Pfeffer MA: Kidney disease and cardiovascular risk. Annu Rev Med 2007;58:123-139.
79.
Larsson TE, et al: Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010;30:333-339.
80.
Gutierrez OM, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
81.
Noordzij M, et al: Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline. Blood Purif 2008;26:231-237.
82.
Lee SK, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-3561.
83.
Armbrecht HJ, et al: Induction of the vitamin D 24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 is regulated by parathyroid hormone in UMR106 osteoblastic cells. Endocrinology 1998;139:3375-3381.
84.
Shinki T, et al: Parathyroid hormone inhibits 25-hydroxyvitamin D3-24-hydroxylase mRNA expression stimulated by 1 alpha,25-dihydroxyvitamin D3 in rat kidney but not in intestine. J Biol Chem 1992;267:13757-13762.
85.
Brenza HL, DeLuca HF: Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. Arch Biochem Biophys 2000;381:143-152.
86.
Jeong HS, Dominguez AR: Calciphylaxis: controversies in pathogenesis, diagnosis and treatment. Am J Med Sci 2016;351:217-227.
87.
Holick MF: Vitamin D deficiency. N Engl J Med 2007;357:266-281.
88.
Liu WC, et al: Pleiotropic effects of vitamin D in chronic kidney disease. Clin Chim Acta 2016;453:1-12.
89.
Pilz S, et al: Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011;58:374-382.
90.
Schottker B, et al: Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ 2014;348:G3656.
91.
Cheng Z, Lin J, Qian Q: Role of vitamin D in cognitive function in chronic kidney disease. Nutrients 2016;8:pii:E291.
92.
Mehrotra R, et al: Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1144-1151.
93.
Andrukhova O, et al: FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 2012;51:621-628.
94.
Prie D, Friedlander G: Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol 2010;5:1717-1722.
95.
Krajisnik T, et al: Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-131.
96.
Koizumi M, Komaba H, Fukagawa M: Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. Contrib Nephrol 2013;180:110-123.
97.
Isakova T, et al: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-1378.
98.
Scialla JJ, et al: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014;25:349-360.
99.
Faul C, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
100.
Fliser D, et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-2608.
101.
Isakova T, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-2439.
102.
Jamal SA, et al: Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382:1268-1277.
103.
Sekercioglu N, et al: Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLoS One 2016;11:e0156891.
104.
Patel L, Bernard LM, Elder GJ: Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 2016;11:232-244.
105.
de Francisco AL, et al: Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-3717.
106.
Covic A, et al: A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 2013;28:2383-2392.
107.
De Schutter TM, et al: Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 2013;83:1109-1117.
108.
Neven E, et al: A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats. PLoS One 2014;9:e107067.
109.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-S130.
110.
Miskulin DC, et al: Ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency: a randomized clinical trial. J Am Soc Nephrol 2016;27:1801-1810.
111.
Perez-Ricart A, et al: Effectiveness of cinacalcet in patients with chronic kidney disease and secondary hyperparathyroidism not receiving dialysis. PLoS One 2016;11:e0161527.
112.
Tominaga Y, et al: Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 2008;12(suppl 1):S21-S26.
113.
Blagodatski A, Poteryaev D, Katanaev VL: Targeting the Wnt pathways for therapies. Mol Cell Ther 2014;2:28.
114.
Carrillo-Lopez N, et al: Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 2016;90:77-89.
115.
Frenkel WN, et al: The association between serum sodium levels at time of admission and mortality and morbidity in acutely admitted elderly patients: a prospective cohort study. J Am Geriatr Soc 2010;58:2227-2228.
116.
Holland-Bill L, et al: Hyponatremia and mortality risk: a Danish cohort study of 279 508 acutely hospitalized patients. Eur J Endocrinol 2015;173:71-81.
117.
Liamis G, et al: Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med 2013;126:256-263.
118.
Miller M, Morley JE, Rubenstein LZ: Hyponatremia in a nursing home population. J Am Geriatr Soc 1995;43:1410-1413.
119.
Olsson K, Ohlin B, Melander O: Epidemiology and characteristics of hyponatremia in the emergency department. Eur J Intern Med 2013;24:110-116.
120.
Zilberberg MD, et al: Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin 2008;24:1601-1608.
121.
Palevsky PM, Bhagrath R, Greenberg A: Hypernatremia in hospitalized patients. Ann Intern Med 1996;124:197-203.
122.
Zhang YZ, Qie JY, Zhang QH: Incidence and mortality prognosis of dysnatremias in neurologic critically ill patients. Eur Neurol 2015;73:29-36.
123.
Kovesdy CP, et al: Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012;125:677-684.
124.
Corona G, et al: Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One 2015;10:e0124105.
125.
Berl T: Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 2008;19:1076-1078.
126.
Adrogue HJ, Madias NE: Hypernatremia. N Engl J Med 2000;342:1493-1499.
127.
Huang H, et al: Associations of dysnatremias with mortality in chronic kidney disease. Nephrol Dial Transplant 2016;pii:gfw209.
128.
Ravel VA, et al: Serum sodium and mortality in a national peritoneal dialysis cohort. Nephrol Dial Transplant 2016;pii:gfw254.
129.
Rhee CM, et al: Pre-dialysis serum sodium and mortality in a national incident hemodialysis cohort. Nephrol Dial Transplant 2016;31:992-1001.
130.
Cheungpasitporn W, Thongprayoon C, Qian Q: Dysmagnesemia in hospitalized patients: prevalence and prognostic importance. Mayo Clin Proc 2015;90:1001-1010.
131.
Sakaguchi Y, et al: Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014;85:174-181.
132.
Yang X, et al: Serum magnesium levels and hospitalization and mortality in incident peritoneal dialysis patients: a cohort study. Am J Kidney Dis 2016;68:619-627.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.